Literature DB >> 2627976

Correlation of proliferative activity with pathological features in breast carcinoma.

P G Betta1, F Robutti, F P Pilato, G Spinoglio, G Bottero.   

Abstract

A presently undefined nuclear antigen recognized by the monoclonal antibody Ki-67, and the transferrin receptor (TR), both expressed by proliferating cells, were visualized in cryostat sections of 40 consecutive cases of primary breast cancer using a three-step immunoperoxidase technique. The percentages of Ki-67 and TR positive cells were determined. A strong positive correlation was observed between these two indices of proliferation (p less than 0.01). Moreover, each of them was positively related to the histological tumour grade (p less than 0.01), although the scatter in the number of proliferating cells within each grade was large. No significant relation (p greater than 0.05) was found between the percentages of Ki-67 and TR positive cells and tumor size and between these values and axillary node status. These correlations are similar to those recently reported in the relevant literature and suggest that immunohistochemical assessment of proliferative activity may prove to be an objective indicator of biological behaviour and therefore be of clinical and therapeutical importance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2627976

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  2 in total

1.  Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications.

Authors:  Daehoon Park; Rolf Kåresen; Tove Noren; Torill Sauer
Journal:  Virchows Arch       Date:  2007-06-07       Impact factor: 4.064

2.  Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival.

Authors:  S E Pinder; P Wencyk; D M Sibbering; J A Bell; C W Elston; R Nicholson; J F Robertson; R W Blamey; I O Ellis
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.